Catalyst Dossier · compiled by CeliA 🧫

Ipsen S.A. (IPN.PA)

Pharmaceutical Preparations · market cap $14.5B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-31 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Ipsen S.A. (IPN.PA) is a mid-cap specialty pharmaceutical company with approximately 5,535 employees and a market cap of ~$14.5B. Its pipeline spans multiple Phase 3 programs including lanreotide (Autogel), odevixibat, botulinum toxin type A, and Smecta across gastrointestinal and neurological indications. No near-term catalysts are flagged in the calendar, and key financial details (cash, net debt, revenue, R&D spend) were not provided in the sourced facts.

The catalyst path

2026-08-31 (est.)Phase 2 · IPN10200imp 7/10

Pipeline

Asset	Phase	Indication
Elafibranor	Phase 3	Primary Biliary Cholangitis (PBC)
IPN10200	Phase 3	Moderate to Severe Glabellar Lines
Lanreotide autogel 120 mg	Phase 2	Pancreatic Tumours
Lanreotide autogel	Phase 3	Gastroenteropancreatic Neuroendocrine Tumor
lanreotide (Autogel formulation)	Phase 3	Diarrhea
Odevixibat	Phase 3	Alagille Syndrome
Botulinum toxin type A	Phase 3	Cervical Dystonia
Smecta (Diosmectite), duration of treatment - 7 days	Phase 3	Diarrhoea

Price & technical context

3-month

+3.4%

6-month

+39.3%

12-month

+60.2%

52-wk range

$102.50–$172.90

vs 50-day MA

+3.0%

vs 200-day MA

+17.3%

Realized vol

27.4%

Max drawdown

-12.5%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IPN.PA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.